A busy week at BenevolentAI Limitedhas seen the artificial intelligence drug discovery and developer ink a potentially lucrative deal with Merck KGaA while Joanna Shields has stepped down as CEO as the UK firm presses on with its restructuring plan.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?